PATENT
674519-2030

AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

In the Claims:

1. (Previously Presented) A compound having Formula VIII



Formula VIII

wherein G is H, OH or a hydrocarbyl group, and wherein R^1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group.

2-7. (Cancelled)

8. (Original) A compound according to claim 1 having Formula XII



Formula XII

9. (Currently Amended) A compound according to claim 1 wherein the hydrocarbyl group is selected from the group consisting of ~~an optionally substituted hydrocarbon group,~~ an optionally substituted alkyl group, an optionally substituted haloalkyl group, an aryl group, an alkylaryl group, an alkylarylalkyl group and an alkene group.

10-11. (Cancelled)

12. (Currently Amended) A compound according to claim 1 wherein ~~G or~~ the hydrocarbyl group is selected from the group consisting essentially of:

a C_1-C_{10} alkyl group, ~~a C_1-C_6 alkyl group, a C_1-C_3 alkyl group;~~

C_1-C_{10} haloalkyl group, ~~a C_1-C_6 haloalkyl group, a C_1-C_3 haloalkyl group;~~

C_1-C_{10} bromoalkyl group, ~~C_1-C_6 bromoalkyl group, C_1-C_3 bromoalkyl group;~~

-$(CH_2)_{1-10}$ aryl, -$(CH_2)_{1-10}$-Ph, $(CH_2)_{1-10}$-Ph-C_{1-10} alkyl, ~~-$(CH_2)_{1-5}$-Ph, $(CH_2)_{1-5}$-Ph-C_{1-5} alkyl, -$(CH_2)_{1-3}$-Ph, $(CH_2)_{1-3}$-Ph-C_{1-3} alkyl, -CH_2-Ph, CH_2-Ph-$C(CH_3)_3$,~~ -$(CH_2)_{1-10}$ cycloalkyl, -$(CH_2)_{1-10}$-C_{3-10}cycloalkyl, ~~-$(CH_2)_{1-7}$-C_{3-7}cycloalkyl, $(CH_2)_{1-5}$-C_{3-5}cycloalkyl, -$(CH_2)_{1-3}$-C_{3-5}cycloalkyl, -CH_2-C_3cycloalkyl;~~ and,

an alkene, a C_1-C_{10} alkene group, ~~a C_1-C_6 alkene group, a C_1-C_3 alkene group~~.

13-17. (Cancelled)

18. (Original) A compound according to claim 1 wherein G is H.

19. (Original) A compound according to claim 1 wherein R^1 is a sulphamate group.

20. (Currently Amended) A compound according to claim 1 wherein R^1 or the sulphamate group is of the formula



wherein R^4 and R^5 are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl. or combinations thereof, or together represent alkylene, wherein the alkylene ~~or each alkyl or cycloalkyl or alkenyl or aryl~~ optionally contains one or more hetero atoms or groups.

21. (Original) A compound according to claim 20 wherein at least one of $R^4$and $R^5$is H.

22. (Original) A compound according to claim 21 wherein R^4 and R^5 are H.

23. (Currently Amended) A compound according to claim 1 having Formula XII



Formula XII

wherein G is selected from H, OH, C_1-C_{10} alkyl, C_1-C_{10} haloalkyl, -$(CH_2)_{1-10}$-aryl, -$(CH_2)_{1-10}$-cycloalkyl, and C_1-C_{10} alkene;

wherein R^1 is OH or a sulphamate group of the formula



wherein $R^4$and R^5 are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the alkylene ~~or each alkyl or cycloalkyl or alkenyl or aryl~~ optionally contains one or more hetero atoms or groups.

24. (Original) A pharmaceutical composition comprising a compound according to claim 1 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

25-30. (Cancelled)

31. (Previously Presented) A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in claim 1; (b) determining whether one or more of said candidate compounds is/are capable of inhibiting steroid sulphatase activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting steroid sulphatase activity.

32. (Cancelled)

33. (Original) A compound identified by the method according to claim 31.

34-36. (Cancelled)

37. (Original) A pharmaceutical composition comprising the compound according to claim 33 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

38-54. (Cancelled)